Event Phase 2 Rate (12 mg group) Phase 2 Rate (Placebo) Nausea 45.8% 11.6% Diarrhea 33.3% 9.3% Vomiting 22.2% 2.3% Constipation 16.7% 7.0% Decreased appetite 22.2% 2.3% The nausea incidence at the highest dose a nausea percentage of roughly 46% makes it the single most reported adverse event in retatrutide clinical trials 2026 data
In recent years, GLP-1 approvals have expanded beyond blood sugar management and weight loss to include other organs, like the heart, kidneys, and liver
Mansoori, N., Tripathi, M., Luthra, K., Alam, R., Lakshmy, R
Aim for at least 23 liters of fluid daily, prioritizing water, herbal tea, and electrolyte solutions
It is not approved for use in people with type 1 diabetes, in children or in pregnancy